David Mclntosh: Expanding Plasma Protein Therapies in Underserved Regions
David McIntosh, Founder and Chair of United Plasma Action, shared a post by Generic Pharma Hub on LinkedIn:
“A Real Cause for Celebration
As the traditional annual Plasma Awareness Week rolls up, it is enormously refreshing to see this webinar included in the schedule.
Here we have a team actually addressing and confronting the key task – not of finding new ways to celebrate alleged success – but of actually changing the chronically inadequate Status Quo – AND to a quantified time-line.
The notion of asking what needs to be done to improve the global plasma medicines situation by or before 2035 may sound like standard good practice in any field with a currently sub-optimal performance, but it is in fact revolutionary – and it’s exactly what’s needed, right here, right now.
This event must surely be a vital part of the week’s activities for everyone with a serious interest in extending and improving the Plasma Community’s reach to the underserved majority of rare disease sufferers, worldwide.
It is estimated that some 80% of patients currently have little or no access to the life-saving and life-enhancing plasma-derived medicines that they so badly need.
It is to relieving their plight that we must surely dedicate our efforts in the years ahead.
The output from the October 6th webinar, will surely form an important part of that dedication!”
Generic Pharma Hub shared a post on LinkedIn:
“Prof. Thierry Burnouf has spent decades advancing the science of plasma fractionation, therapeutic plasma proteins and blood safety.
His work spans plasma protein purification, pathogen safety and the development of approaches to make plasma-derived medicinal products safer and more accessible, particularly in regions where access remains limited.
At Plasma 2035: Emerging Scene – Plasma Protein Therapy, he brings the scientific perspective to the conversation – connecting plasma resources, fractionation capability and safety with the larger challenge of ensuring these therapies ultimately reach patients.
Join us as we explore what needs to change by 2035 to make safe and effective plasma protein therapies more accessible, particularly in developing countries.
October 6, 2026
11:00 AM IST
Register.”

More posts featuring David McIntosh on Hemostasis Today.
-
Nov 11, 2026, 15:42Tareq Abadl: The Clinical Impact of Kell Alloimmunization
-
Nov 11, 2026, 15:30Alejandro González Veliz: Does PCI Change The Long-Term Outcome In Stable Coronary Artery Disease?
-
Nov 11, 2026, 15:25Preparing for the SoHO Regulation – EBA Board Convenes in Vienna – European Blood Alliance
-
Nov 11, 2026, 15:20Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies
-
Nov 11, 2026, 15:03Maria Elisa Mancuso: World-Renowned Faculty and 33 Global Participants Unite at Hemophilia Academy 2026
-
Nov 11, 2026, 15:01Hassan Raza: The JAK2 V617F Revolution
-
Nov 11, 2026, 14:57Edward Lee Carter: Factor Xla Inhibition Enters Clinical Practice – FDA Approval of Asundexian